ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals Inc.

In a report released yesterday, from Oppenheimer maintained a Buy rating on ARS Pharmaceuticals, with a price target of $35.00. The company’s share...

ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer

Ars Pharmaceuticals, Inc. (($SPRY)) announced an update on their ongoing clinical study. Study Overview: Ars Pharmaceuticals, Inc. is conducting a ...

Market Cap	$888.65M	P/E Ratio	N/A
52W High	$18.90	52W Low	$6.73
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	26.6%	52W Position	7.1%
Overall Score	29	Value Score	50
Quality Score	--	Technical Score	9

EPS Current Est	$-1.74	EPS Next Est	$-1.25
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$7.59	+12.78%	3.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$7.59	+12.8%	3.90M
3
4
5
6

SPRY

SPRY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ARS Pharmaceuticals Inc. Data in Excel

Get ARS Pharmaceuticals Inc. Data in Excel